BioHealth & Medical Analyst Calls (AZN, NVS, NVO, CRL, IVGN, APPY, TWTI)
BNP Paribas overseas has lowered ratings of AstraZeneca (NYSE: AZN) to Underperform from Neutral; and raised Novartis (NYSE: NVS) to Neutral from Underperform.
Goldman Sachs has raised Novo Nordisk (NYSE: NVO) to Buy from Neutral; Charles River Laboratories (NYSE: CRL) downgraded to Neutral at Goldman Sachs.
JPMorgan has raised its rating on Invitrogen (NASDAQ: IVGN) to Overweight from Neutral.
Lazard Capital Markets started coverage of Aspenbio (NASDAQ: APPY) with a “Buy” rating.
R.W.Baird Downgraded Third Wave Technologies (NASDAQ: TWTI) to Neutral from Outperform.
Jon Ogg
June 24, 2008
Analyst Research Calls Impacting Biotechs (ALXN, OSCI, SGMO, VVUS, CRA)
There were some research calls that are affecting many shares of biotech stocks this morning, as follows:
- Alexion Pharmaceuticals (NASDAQ: ALXN) started as Buy at Piper Jaffray, shares up almost 2%.
- Oscient Pharmaceuticals (NASDAQ: OSCI) started as Neutral at Piper Jaffray; shares flat as a thin volume stock.
- Sangamo Biosciences (NASDAQ: SGMO) Started as Sell at Brean Murray; shares down 11%
- Vivus (NASDAQ: VVUS) Cut to Market Perform from Outperform at Wachovia; shares down some 4%.
Elsewhere, Celera Genomics (NYSE: CRA) was started with a “Perform” rating at Oppenheimer. While Celera is a molecular diagnostic company, they are involved in the identification and validation of diagnostic markers using their own proprietary genomics and proteomics discovery platforms.
Jon Ogg
May 29, 2008